Navigation Links
Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
Date:3/16/2009

AURORA, Ontario, March 16 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") announced that it has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

The clinical study was designed, as mandated by regulatory authorities, to gather data on the absorption and elimination profile of Topical Interferon Alpha-2b in patients with low-grade cervical lesions, in addition to further data on its safety and efficacy. Depending on the data generated in the study, it is expected that interim results, which Helix anticipates will be received during its fiscal fourth quarter 2009, will allow the company to proceed with its planned regulatory filings in the U.S. and Europe respectively for its future Phase IIb and Phase III pivotal efficacy trials for this indication.

"This clinical study will build upon our previous clinical findings and increase our understanding of the drug's pharmacokinetic profile in patients with low-grade cervical lesions," said John Docherty, president of Helix BioPharma. "Receiving the necessary approvals to commence this study is a significant step as we continue to advance the clinical development of Topical Interferon Alpha-2b for this important therapeutic indication."

About the Clinical Study

The primary objective of the clinical study is to determine the multiple-dose pharmacokinetic profile of Topical Interferon Alpha-2b following intravaginal application every other day of a total of 14 doses of the cream. Following the pharmacokinetic portion of the trial, assessment of efficacy and safety parameters will continue until 35 doses of the cream have been applied. As such, the clinical study is designed to also provide support for the dosing regimen intended to be applied in the future to U.S. Phase IIb and European Phase III p
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Research and Markets has announced the addition ... report to their offering.  http://photos.prnewswire.com/prnh/20130307/600769 ... vitro growth of plant or animal cells for several ... Cell culture is a crucial step in tissue engineering ... consumables are necessary for the in vitro production of ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
(Date:7/24/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company ... today announced that the Company will issue a business ... Monday, August 18, 2014 for shareholders. Management has scheduled ... August 18, 2014 to discuss the company,s progress to ... Anthony Hayes . Following prepared remarks, management ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Spherix Schedules Shareholder Update Call 2
... Yang, Associate Professor of Mechanical Engineering and Director of ... Technology, The Innovation University (TM), will receive funding from ... a Nanoimprint Lithography System (NIL) for the purpose of ... Stevens. The Co-PIs of the project are Drs. Besser, ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... the safety and efficacy of Caldolor® ( ibuprofen ) ... ill adults. Published in the peer-reviewed journal Critical ... significantly more effective at reducing fever in hospitalized patients ...
... Castle Access, Inc. announces the appointment of ... the Castle Access organization with that of its ... provider, and gives clients in Southwestern US and ... data center and mission-critical managed services. ...
Cached Biology Technology:Nanoimprint lithography NSF grant awarded to micro device lab at Stevens 2Nanoimprint lithography NSF grant awarded to micro device lab at Stevens 3Newly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients 2Newly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients 3Newly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients 4Castle Access Names New Managing Director 2Castle Access Names New Managing Director 3
(Date:7/25/2014)... A study published online in the International ... novel approach to preventing cervical cancer based on findings ... after removal of a discrete population of cells in ... study that looked at squamocolumnar junction cells, or SCJ ... have been implicated as the origins of cervical cancer. ...
(Date:7/25/2014)... of Adelaide has opened the way for the development of ... In Australia, annual barley production is second only to wheat ... of the most important diseases of barley. , Senior Research ... of special growths on the cell walls of barley plants ... , The research, by the ARC Centre of Excellence in ...
(Date:7/25/2014)... that the age girls reach puberty is influenced by ,imprinted ... parent contributes the gene. This is the first evidence ... birth and details of this study were published today in ... period, known as menarche, is a marker for the timing ... onset of menses varies between girls, is an inherited trait, ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2New hope for powdery mildew resistant barley 2Could age of first period influence development of diseases in older women? 2
... reveals critical molecular events in the origin of fat ... such as obesity and diabetes, as fat cells produce ... The study finds that a hormonal cocktail routinely used ... the transition from fat-cell precursors to full-blown fat, researchers ...
... study reveals critical molecular events in the origin of ... diseases, such as obesity and diabetes, as fat cells ... , The study finds that a hormonal cocktail routinely ... in the transition from fat-cell precursors to full-blown fat, ...
... how a common fish found along the West Coast can ... The study marks the first time that scientists have found ... vertebrate's brain that controls the vocal muscle system and the ... that understanding the auditory system of the plainfin midshipman fish ...
Cached Biology News:Key To Stem Cell Transplant Success Is Tricking Immune System 2Short-term Bio Sensors Monitor From Afar 2How fish hear and make sounds at same time 2
Request Info...
1+ mg expected yield of purified protein, expressed in insect cells - excludes cDNA...
... bioinformatics software that has changed the way ... design of BioNumerics allows for integration and ... data employed for the characterization of organisms ... protein gels, HPLC, VNTR, MLST, SNP, fatty ...
Request Info...
Biology Products: